Analysis for CME

📈 Growth & Financial Trajectory

Over eight quarters CME Group shows an overall uptrend in Revenue from about $1.49B in 2024 Q1 to about $1.88B in 2026 Q1, despite a mid-period dip in 2025 Q3–Q4. Net Income rose from about $0.86B to about $1.15B in 2026 Q1, confirming improving profitability even with quarterly volatility. The sequence highlights stronger late-2025 performance, aided by one-off tax/benefit effects, followed by sustained revenue expansion into 2026.

💰 Margins & Cash Flow

Net income margin remains high across quarters, averaging around the mid-50s to low-60s percent, peaking in 2025 Q4 due to tax/benefit items. Operating cash flow has been positive each quarter, with quarterly cash flow from operating activities typically around $0.9B–$1.3B and continuing cash flow often positive, supported by sizable financing inflows in late 2024–2025.

🛡️ Balance Sheet & Liquidity

Total assets around $202B vs liabilities near $175B and equity about $26.6B. Current assets approximate $169.0B and current liabilities around $166.0B, yielding a tight but adequate current ratio (~1.02). Leverage remains visible but resilience is supported by sizable liquidity and a strong equity base.

⚠️ Key Drivers & Risks

• Drivers: (1) Exchange-traded derivatives and data-center demand; (2) market structure stability and clearing volumes.
• Risks: (1) Regulatory/compliance exposure and cyclicality; (2) leverage and sensitivity to interest-rate environment.